NCT07116915View on ClinicalTrials.gov

A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation Administered in Healthy Subjects and Multiple Doses in Patients With COPD

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 11, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

COPD

Interventions

DRUG

HRS-9821 Powder for Inhalation.

DRUG

HRS-9821 Powder for Inhalation placebo

DRUG

Moxifloxacin Hydrochloride Tablets

Trial Locations (1)

610044

RECRUITING

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY

NCT07116915 - A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics for a Single Dose of HRS-9821 Powder for Inhalation Administered in Healthy Subjects and Multiple Doses in Patients With COPD | Biotech Hunter | Biotech Hunter